UP!

IDXX $477.79

IDXX target price
477.79
0
582
IDEXX Laboratories, Inc.
Type
Public
Traded as
  • NASDAQ: IDXX
  • NASDAQ-100 component
  • S&P 500 component
Industry Healthcare Diagnostic Substances
Founded 1983 (1983)
Headquarters Westbrook, Maine, United States
Key people
  • Jonathan W. Ayers (Chief Executive Officer, President, and Chairman)
  • Brian P. McKeon (Chief Financial Officer)
  • (as of 31 December 2016)
Revenue $ 1.77B (as of 31 December 2016)
Number of employees
7,000 (as of 31 December 2016)
Website Idexx.com

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is an American multinational corporation on the S&P 500 and NASDAQ-100 indices engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 and headquartered in Westbrook, Maine, and EMEA in Hoofddorp, Netherlands, IDEXX offers products to customers in over 175 countries around the world and employs approximately 7,000 people in full-and part-time positions (as of 31 December 2016). There are three main segments of the company: Companion Animal Group, Water, and Livestock, Poultry and Dairy (LPD). In addition, the company also manufactures and sells pet-side SNAP tests for a variety of animal health diagnostic uses.

The Companion Animal Group ("CAG") provides in-clinic laboratory analyzers for companion animals. Analyzers measure blood cell counts as well as levels of certain enzymes in blood or urine for the purpose of monitoring health conditions. Major products of this segment are the Catalyst Dx Chemistry Analyzer and the VetTest Chemistry Analyzer, Symmetric dimethylarginine (SDMA), ProCyte Dx Hematology Analyzer, the LaserCyte Hematology Analyzer, the IDEXX VetAutoread Hematology Analyzer, the SNAP Pro analyzer, and so on, among other laboratory equipment and analytical services. Other areas of the CAG division are centered on diagnostic imaging and veterinary practice management software systems, including the flagship program Cornerstone, as well as DVMax (acquired from Sneakers Software, Inc., a New York City-based company, under terms of Ch. 11 reorganization [1]) in late 2012 [2]) and several legacy practice management software systems.

The Water segment provides products to measure microbiological parameters in water. Products of this segment include the Colilert, Colilert-18, and Colisure tests. Water products are sold in over 120 countries around the globe.

The Livestock and Poultry Diagnostics division provides products to detect diseases in livestock and poultry. Products of this segment include tests for Avian Infuenza (AI), Bovine Viral Diarrhea Virus (BVDV), Porcine Reproductive and Respiratory Syndrome (PRRS), and Bovine Spongiform Encephalopathy (BSE or mad cow disease).


Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2022 2023-02-06 Future report Set alerts
Q3 2022 2022-11-01 2.15 2.15
Q2 2022 2022-08-02 1.56 1.56
Q1 2022 2022-05-04 2.27 2.27
Q4 2021 2022-02-02 1.89 1.89
Q3 2021 2021-11-02 2.03 2.03
Q2 2021 2021-07-30 2.34 2.34
Q1 2021 2021-05-04 2.35 2.35
Q4 2020 2021-02-02 2.01 2.01
Q3 2020 2020-10-29 1.69 1.69

Ratings

2016-04-19 Reiterated Rating Canaccord Genuity Buy $80.00 to $85.00
2016-04-13 Boost Price Target Credit Suisse Outperform $80.00 to $85.00
2016-04-13 Boost Price Target Credit Suisse Group AG Outperform $80.00 to $85.00
2016-04-01 Initiated Coverage CL King Neutral
2016-03-21 Boost Price Target Stifel Nicolaus Buy $80.00 to $85.00
2016-02-03 Initiated Coverage Credit Suisse Outperform $80.00
2016-02-01 Reiterated Rating Piper Jaffray Neutral $73.00 to $75.00
2016-02-01 Reiterated Rating Canaccord Genuity Buy $80.00
2016-02-01 Reiterated Rating Piper Jaffray Cos. Neutral $73.00 to $75.00
2016-01-31 Reiterated Rating William Blair Outperform
2016-01-22 Reiterated Rating Canaccord Genuity Buy $80.00
2015-10-30 Reiterated Rating Canaccord Genuity Buy $80.00
2015-10-29 Lower Price Target Stifel Nicolaus Buy $85.00 to $80.00
2015-10-18 Reiterated Rating Canaccord Genuity Buy $87.00
2015-08-28 Downgrade Raymond James Outperform to Market Perform
2015-08-28 Downgrade Raymond James Financial Inc. Outperform to Market Perform
2015-08-13 Boost Price Target Stifel Nicolaus Buy $78.00 to $85.00
2015-08-10 Boost Price Target Piper Jaffray Neutral $70.00 to $77.00
2015-07-23 Lower Price Target Canaccord Genuity Buy $80.00 to $75.00
2015-07-23 Upgrade Feltl & Co. Sell to Hold $61.50 to $69.50
2015-06-29 Reiterated Rating Canaccord Genuity Buy $80.00
2015-05-28 Reiterated Rating Bank of America Buy $168.00
2015-05-28 Reiterated Rating Bank of America Corp. Buy $168.00
2015-04-29 Lower Price Target Stifel Nicolaus Buy $178.00 to $155.00
2015-04-28 Lower Price Target Canaccord Genuity Buy $175.00 to $160.00
2015-04-17 Set Price Target Stifel Nicolaus Buy $178.00
2015-02-15 Reiterated Rating Canaccord Genuity Buy $175.00
2015-02-02 Reiterated Rating Piper Jaffray In-Line to Neutral $160.00
2015-01-22 Reiterated Rating Canaccord Genuity Buy $160.00 to $175.00
2015-01-16 Boost Price Target Stifel Nicolaus Buy $155.00 to $178.00
2014-12-10 Boost Price Target Canaccord Genuity Buy $153.00 to $160.00
2014-10-28 Boost Price Target Canaccord Genuity Buy $139.00 to $153.00
2014-10-27 Boost Price Target Stifel Nicolaus Buy $135.00 to $155.00
2014-09-15 Lower Price Target Canaccord Genuity Buy $148.00 to $139.00
2014-08-20 Downgrade Northcoast Research Neutral to Sell
2014-07-28 Boost Price Target Piper Jaffray $125.00 to $126.00
2014-06-24 Upgrade Canaccord Genuity Hold to Buy $116.00 to $148.00
2014-04-28 Boost Price Target Raymond James Outperform $123.00 to $135.00
2014-04-14 Boost Price Target Stifel Nicolaus Buy $120.00 to $135.00
2014-03-10 Initiated Coverage Piper Jaffray Neutral $121.00 to $125.00
2014-02-05 Boost Price Target Canaccord Genuity $99.00 to $116.00
2014-01-30 Downgrade Feltl & Co. Hold to Sell
2013-11-14 Reiterated Stifel Buy $110 to $120
2013-11-14 Boost Price Target Stifel Nicolaus Buy $110.00 to $120.00
2013-07-15 Upgrade Stifel Hold to Buy $110
2012-03-15 Initiated Feltl & Co. Hold $87.50
2010-05-20 Reiterated Kaufman Bros Buy $77 to $75
2010-04-27 Reiterated Kaufman Bros Buy $70 to $77
2010-04-07 Initiated Kaufman Bros Buy $70
2010-02-01 Downgrade Avondale Mkt Perform to Mkt Underperform $42
2009-06-15 Downgrade Avondale Mkt Outperform to Mkt Perform
2008-10-15 Initiated Avondale Mkt Outperform $55
2008-09-26 Initiated Sun Trust Rbsn Humphrey Neutral
2007-12-14 Initiated JP Morgan Overweight
2007-08-24 Reiterated CL King Strong Buy $105 to $125
2016-04-19 Reiterated Rating Canaccord Genuity Buy $80.00 to $85.00
2016-04-13 Boost Price Target Credit Suisse Outperform $80.00 to $85.00
2016-04-13 Boost Price Target Credit Suisse Group AG Outperform $80.00 to $85.00
2016-04-01 Initiated Coverage CL King Neutral
2016-03-21 Boost Price Target Stifel Nicolaus Buy $80.00 to $85.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
AYERS JONATHAN W Chairman, President & CEO 2.12%  (1063398) IDXX /
Williams Michael J PhD Executive Vice President 0.12%  (59113) IDXX /
MCKEON BRIAN P 0.09%  (44040) ATHN / IDXX /
END WILLIAM T 0.08%  (41256) IDXX /
MURRAY ROBERT J 0.07%  (36347) IDXX / LOJN / THG / TUP /
RAINES MERILEE Executive VP & CFO 0.05%  (26577) AFFX / IDXX / PETX / WTS /
POWERS JOHNNY D Executive Vice President 0.05%  (25961) IDXX /
CRAIG THOMAS 0.05%  (24471) IDXX /
MAZELSKY JAY Executive Vice President 0.04%  (20760) IDXX /
HENDERSON REBECCA M 0.04%  (19852) AMGN / IDXX /
NAQUI ALI Corporate Vice President 0.03%  (17513) IDXX /
BROWN WILLIAM E III Executive Vice President 0.03%  (17259) IDXX /
TWIGGE GIOVANI CORPORATE VICE PRESIDENT 0.03%  (15738) IDXX /
POLEWACZYK JAMES F Corporate Vice President 0.01%  (6955) IDXX /
Vandebroek Sophie V. 0.01%  (6096) ALOG / IDXX /
Studer Jacqueline CVP, Gen. Counsel & Secretary 0.01%  (5077) IDXX / MDRX /
Kingsley Lawrence D 0.01%  (4654) IDXX / IEX / PII / PLL / ROK /
Meyaard Daniel V Corporate Vice President 0.01%  (4416) IDXX /
JOHNSON BARRY C 0.01%  (3560) CYT / IDXX / ROK /
JUNIUS DANIEL M 0.01%  (2659) GLYC / IDXX / IMGN / VTAE /